Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
Stefan Pool(Erasmus MC), Marion de Jong(Shell (Netherlands)), Jaap J.M. Teunissen(Erasmus MC), Gerben A. Koning(Università Cattolica del Sacro Cuore), Boen L.R. Kam(Erasmus MC), Dik J. Kwekkeboom(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Roelf Valkema(Active Medicine (United Kingdom))
Cited by 98
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914